November 17, 2026
Giredestrant Approval Up to 40% of people with hormone receptor-positive metastatic breast cancer develop ESR1 mutations, which help tumours escape standard hormone therapy. On November 16, the FDA approved giredestrant (Wilserdly) in combination with everolimus for adults whose advanced breast cancer carries one of these mutations, four weeks ahead of […]
